Hot Features
Dimerix Limited, a biopharmaceutical company, develops and commercializes pharmaceutical products for unmet medical needs in Australia. It develops DMX-200 for the treatment of focal segmental glomerulosclerosis disease, diabetic kidney disease, and ARDS associated with COVID-19; and DMX-700 for orp... Dimerix Limited, a biopharmaceutical company, develops and commercializes pharmaceutical products for unmet medical needs in Australia. It develops DMX-200 for the treatment of focal segmental glomerulosclerosis disease, diabetic kidney disease, and ARDS associated with COVID-19; and DMX-700 for orphan respiratory/renal disease, as well as proprietary Receptor-HIT assay technology. The company is headquartered in Fitzroy, Australia. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.0175 | -9.21052631579 | 0.19 | 0.19 | 0.165 | 2060356 | 0.17794973 | DE |
| 4 | -0.0275 | -13.75 | 0.2 | 0.23 | 0.165 | 2064335 | 0.20079528 | DE |
| 12 | -0.1975 | -53.3783783784 | 0.37 | 0.42 | 0.165 | 2065068 | 0.24870765 | DE |
| 26 | -0.3475 | -66.8269230769 | 0.52 | 0.665 | 0.165 | 1651820 | 0.36197429 | DE |
| 52 | -0.3975 | -69.7368421053 | 0.57 | 0.665 | 0.165 | 1490456 | 0.43299142 | DE |
| 156 | 0.1055 | 157.462686567 | 0.067 | 0.785 | 0.052 | 2518660 | 0.3830909 | DE |
| 260 | -0.0575 | -25 | 0.23 | 0.785 | 0.052 | 1720967 | 0.36536423 | DE |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.